Loading...
XASX
IMR
Market cap327mUSD
Jun 18, Last price  
1.87AUD
1D
-1.06%
1Q
-4.10%
IPO
52.03%
Name

Imricor Medical Systems Inc

Chart & Performance

D1W1MN
XASX:IMR chart
P/E
P/S
341.38
EPS
Div Yield, %
Shrs. gr., 5y
18.45%
Rev. gr., 5y
8.44%
Revenues
303k
-68.47%
703,919565,5971,342,573639,704702,161696,267816,011615,568959,424302,502
Net income
-26m
L-11.76%
-5,494,861-6,710,723-7,297,118-14,798,147-13,076,801-20,556,113-17,534,184-22,625,902-29,692,831-26,201,489
CFO
-20m
L+26.79%
-4,051,414-5,647,803-6,340,013-6,627,993-12,230,689-17,488,546-16,821,693-19,551,255-15,573,910-19,746,569

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Imricor Medical Systems, Inc. operates as a specialized medical device company focused on developing, manufacturing, and commercializing products that are fully compatible with Magnetic Resonance Imaging (MRI) technology. These devices are specifically designed for use in cardiac catheter ablation procedures performed across the United States. The company's primary product portfolio includes the Advantage-MR EP Recorder/Stimulator system, which functions as both an electrophysiology recording system and an integrated cardiac stimulator. Another key offering is the Vision-MR Ablation Catheter, indicated for the treatment of type I atrial flutter. Imricor also provides the Vision-MR Dispersive Electrode, engineered to minimize eddy currents that can occur on conductive pads during an MRI scan. Beyond its core product development, Imricor engages in contract research activities and licenses its proprietary intellectual property for incorporation into implantable medical devices. Established in 2006, the firm's corporate headquarters are situated in Burnsville, Minnesota.
IPO date
Aug 30, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT